Shin Nippon Biomedical Laboratories Past Earnings Performance
Past criteria checks 2/6
Shin Nippon Biomedical Laboratories has been growing earnings at an average annual rate of 18.5%, while the Life Sciences industry saw earnings growing at 25.6% annually. Revenues have been growing at an average rate of 16.2% per year. Shin Nippon Biomedical Laboratories's return on equity is 12.7%, and it has net margins of 16.3%.
Key information
18.5%
Earnings growth rate
18.5%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | 16.2% |
| Return on equity | 12.7% |
| Net Margin | 16.3% |
| Next Earnings Update | 06 Nov 2024 |
Recent past performance updates
Recent updates
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27Revenue & Expenses Breakdown
How Shin Nippon Biomedical Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 26,195 | 4,280 | 9,729 | 0 |
| 31 Mar 24 | 26,450 | 5,531 | 8,118 | 1,741 |
| 31 Dec 23 | 26,703 | 5,503 | 9,033 | 683 |
| 30 Sep 23 | 26,626 | 4,607 | 7,806 | 683 |
| 30 Jun 23 | 26,848 | 5,489 | 7,520 | 683 |
| 31 Mar 23 | 25,090 | 6,060 | 6,894 | 683 |
| 31 Dec 22 | 21,173 | 6,231 | 6,050 | 425 |
| 30 Sep 22 | 20,135 | 8,043 | 5,648 | 425 |
| 30 Jun 22 | 18,753 | 7,245 | 5,178 | 425 |
| 31 Mar 22 | 17,748 | 7,127 | 4,908 | 425 |
| 31 Dec 21 | 17,636 | 7,432 | 4,803 | 392 |
| 30 Sep 21 | 16,068 | 6,025 | 4,566 | 392 |
| 30 Jun 21 | 14,978 | 4,844 | 4,417 | 392 |
| 31 Mar 21 | 15,110 | 3,661 | 4,482 | 392 |
| 31 Dec 20 | 14,910 | 2,421 | 4,574 | 400 |
| 30 Sep 20 | 15,175 | 2,812 | 4,692 | 400 |
| 30 Jun 20 | 15,004 | 3,234 | 4,764 | 400 |
| 31 Mar 20 | 14,561 | 2,550 | 4,840 | 400 |
| 31 Dec 19 | 13,497 | 1,990 | 4,308 | 339 |
| 30 Sep 19 | 13,167 | 1,915 | 4,175 | 339 |
| 30 Jun 19 | 14,676 | 1,524 | 4,656 | 339 |
| 31 Mar 19 | 15,658 | 1,950 | 4,865 | 339 |
| 31 Dec 18 | 17,337 | -49 | 4,996 | 518 |
| 30 Sep 18 | 17,928 | -993 | 5,251 | 518 |
| 30 Jun 18 | 16,937 | -2,566 | 5,016 | 518 |
| 31 Mar 18 | 16,600 | -3,555 | 5,139 | 518 |
| 31 Dec 17 | 17,186 | -1,072 | 5,081 | 600 |
| 30 Sep 17 | 17,714 | 327 | 5,177 | 600 |
| 30 Jun 17 | 17,230 | 260 | 5,250 | 600 |
| 31 Mar 17 | 17,244 | -915 | 5,301 | 600 |
| 31 Dec 16 | 15,880 | -1,821 | 5,157 | 815 |
| 30 Sep 16 | 15,269 | -1,273 | 5,282 | 815 |
| 30 Jun 16 | 14,922 | -1,475 | 5,390 | 815 |
| 31 Mar 16 | 14,750 | 2,646 | 5,496 | 815 |
| 31 Dec 15 | 15,637 | 2,060 | 5,550 | 739 |
| 30 Sep 15 | 16,344 | 401 | 5,554 | 739 |
| 30 Jun 15 | 17,164 | 1,546 | 5,532 | 739 |
| 31 Mar 15 | 17,835 | -1,385 | 5,579 | 739 |
| 31 Dec 14 | 18,058 | -417 | 5,593 | 747 |
| 30 Sep 14 | 17,161 | -599 | 5,569 | 747 |
| 30 Jun 14 | 17,132 | -1,074 | 5,641 | 747 |
| 31 Mar 14 | 16,926 | -754 | 5,449 | 747 |
| 31 Dec 13 | 16,993 | -1,443 | 5,613 | 577 |
Quality Earnings: 2395 has high quality earnings.
Growing Profit Margin: 2395's current net profit margins (16.3%) are lower than last year (20.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2395's earnings have grown by 18.5% per year over the past 5 years.
Accelerating Growth: 2395's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2395 had negative earnings growth (-22%) over the past year, making it difficult to compare to the Life Sciences industry average (-32.8%).
Return on Equity
High ROE: 2395's Return on Equity (12.7%) is considered low.